Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
N/A N=173 Diagnostic

PET Scan in Treating Patients With Metastatic Prostate Cancer

Prostate Cancer

Bottom Line

View on ClinicalTrials.gov: NCT00002981 ↗
Enrolled (actual)
173
Serious AEs
1.2%
Results posted
Jun 2024
Primary outcome: Primary: Overall Survival — 91.6 weeks

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
positron emission tomography (Procedure); fludeoxyglucose F 18 (Radiation); methionine C 11 (Radiation)
Age
Pediatric, Adult, Older Adult · 0+ yrs
Sex
Male
Sponsor
Memorial Sloan Kettering Cancer Center
Primary completion
Jun 2023

Outcome Measures

OutcomeResultp-value
PRIMARY
Overall Survival		 91.6 —
PRIMARY
Metabolism		 — —
PRIMARY
Percentage of Unbiopsied Lesions That Are Confirmed Positive		 98 —

Summary

RATIONALE: New imaging procedures, such as PET scan, may improve the ability to detect new or recurrent prostate cancer.

Eligibility Criteria

DISEASE CHARACTERISTICS:

  • Histologically confirmed prostate adenocarcinoma
  • Must have an at least 50% increase in PSA which is sustained for a minimum of 3 observations obtained at least 1 week apart
  • Must have development of new lesions on bone scintigraphy or greater than 50% increase in measurable disease on CT or MRI scan
  • Metastatic disease

PATIENT CHARACTERISTICS:

Age:

  • Not specified

Performance status:

  • Karnofsky greater than 60%

Hematopoietic:

  • ANC greater than 1,000/mm^3
  • Platelet count greater than 100,000/mm^3

Hepatic:

  • Not specified

Renal:

  • Not specified

Cardiovascular:

  • No clinically significant cardiac disease

Pulmonary:

  • No clinically significant pulmonary disease

Other:

  • No active infection not controlled by antibiotics

PRIOR CONCURRENT THERAPY:

Biologic therapy

  • Not specified

Chemotherapy

  • Not specified

Endocrine therapy

  • Not specified

Radiotherapy

  • Not specified

Surgery

  • Not specified
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00002981). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search